ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc (LXRX)

2.40
0.21
(9.59%)
Closed March 29 04:00PM
2.42
0.02
(0.83%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.42
Bid
2.37
Ask
2.48
Volume
7,061,172
2.13 Day's Range 2.47
0.92 52 Week Range 3.789
Market Cap
Previous Close
2.19
Open
2.18
Last Trade
65
@
2.42
Last Trade Time
Financial Volume
$ 16,114,762
VWAP
2.2822
Average Volume (3m)
4,882,345
Shares Outstanding
244,924,695
Dividend Yield
-
PE Ratio
-5.74
Earnings Per Share (EPS)
-0.42
Revenue
139k
Net Profit
-101.94M

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lexicon Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LXRX. The last closing price for Lexicon Pharmaceuticals was $2.19. Over the last year, Lexicon Pharmaceuticals shares have traded in a share price range of $ 0.92 to $ 3.789.

Lexicon Pharmaceuticals currently has 244,924,695 shares outstanding. The market capitalization of Lexicon Pharmaceuticals is $585.37 million. Lexicon Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.74.

LXRX Latest News

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial...

Form PRE 14A - Other preliminary proxy statements

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, DC. 20549SCHEDULE 14A(Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENTSCHEDULE 14A INFORMATION Proxy Statement Pursuant to...

Form 8-K - Current report

false 0001062822 --12-31 0001062822 2024-03-06 2024-03-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT...

Lexicon Pharmaceuticals Reports Fourth Quarter 2023ย Financial Results and Provides Business Update

Commercial launch of INPEFAยฎ (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a...

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (โ€œLexiconโ€) today announced it has entered into a securities purchase agreement (the...

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.05-2.024291497982.472.591.9639816042.17251068CS
4-0.2-7.633587786262.622.82911.9649975312.49432829CS
120.8857.14285714291.543.731.2448823452.37228417CS
261.22101.6666666671.23.730.9236611141.92722775CS
520.135.67685589522.293.7890.9227966092.06908616CS
156-3.4-58.41924398635.826.32990.9214492722.54885543CS
260-2.88-54.33962264155.39.650.9218875923.27446842CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

LXRX Discussion

View Posts
dcaf7 dcaf7 2 weeks ago
Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.
👍️ 1
Awl416 Awl416 3 weeks ago
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
๐Ÿ‘๏ธ0
BooDog BooDog 4 weeks ago
Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

Form 4 filed
๐Ÿ‘๏ธ0
jdheart101 jdheart101 1 month ago
200 July 2.5 calls @.88 . Be back soon !!!
๐Ÿ‘๏ธ0
TIMGZ TIMGZ 2 months ago
INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


WITHIN MINUTES*****UPTREND

SEEMS SETTING UP NICELY FOR THAT
๐Ÿ‘๏ธ0
BooDog BooDog 2 months ago
Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
jdheart101 jdheart101 2 months ago
Another 4000. @1.76
๐Ÿ‘๏ธ0
Legend431 Legend431 2 months ago
Oops
๐Ÿ‘๏ธ0
jdheart101 jdheart101 2 months ago
Iโ€™m in today 9500 @1.49 1/23/24
๐Ÿ‘๏ธ0
BooDog BooDog 4 months ago
Ready to see this rock and roll. Get the Christmas rally going!

https://www.inpefahcp.com/


Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014โ€“)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/

https://www.lexpharma.com/media-center/news
๐Ÿ‘๏ธ0
BooDog BooDog 4 months ago
Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
LXRX new 52 week low
๐Ÿ‘๏ธ0
BooDog BooDog 5 months ago
$LXRX. Looking good. See this in a week or 2.

JMHO.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 5 months ago
LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
TRADER99 TRADER99 6 months ago
Looks like we saw a bottom here with this spike in volume
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
LXRX new 52 week low
๐Ÿ‘๏ธ0
BooDog BooDog 6 months ago
Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

Cheers
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
LXRX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
LXRX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
LXRX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
LXRX new 52 week low
๐Ÿ‘๏ธ0
BooDog BooDog 8 months ago
LXRX 1.70's. Watching.
๐Ÿ‘๏ธ0
BooDog BooDog 9 months ago
$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexiconโ€™s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
๐Ÿ‘๏ธ0
BooDog BooDog 10 months ago
๐Ÿ‘๏ธ0
BooDog BooDog 10 months ago
Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
๐Ÿ‘๏ธ0
BooDog BooDog 10 months ago
Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
๐Ÿ‘๏ธ0
TIMGZ TIMGZ 10 months ago
LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX
👍️ 1
BooDog BooDog 10 months ago
2.75 support. See how it holds, or not. Interesting sell off.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 10 months ago
LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
BooDog BooDog 10 months ago
Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 10 months ago
LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
BooDog BooDog 11 months ago
If I se what I think I see, there's a reason shorts are leaving this puppy alone.

Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 11 months ago
LXRX.............................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
BooDog BooDog 11 months ago
High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.

See what this puppy does.


https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100
๐Ÿ‘๏ธ0
BooDog BooDog 11 months ago
Passing 2.69.
๐Ÿ‘๏ธ0
BooDog BooDog 11 months ago
Let's get the move on.
๐Ÿ‘๏ธ0
BooDog BooDog 1 year ago
PUDUFA coming in a couple months. Looks like they're pretty confident.

GLTA
๐Ÿ‘๏ธ0
makinezmoney makinezmoney 1 year ago
$LXRX: Time to load July $3 calls...... now $0.70

Why ????

1. Cash on Hand.............. $138.4Milly
2. Huge Insider buying of shares of $45Milly at $2.50sh
3. Piper Sandler with $10 Overweight assigned back in August last year
4. PDUFA coming in MAY
5. Largest OI is 1k on the July $3 calls


You know what that means right ???? They gotta a good feeling about that PDUFA
$LXRX now at $2.44......... last time it spiked ffrom $1.12 to $9.50 from Nov6,2020 to
Feb1, 2021 ..... 9x bagger !

Round 2 coming


GO $LXRX
๐Ÿ‘๏ธ0
BooDog BooDog 1 year ago
Chart showing some strength. Closes over 2.20 and the bulls will be in the lead for next week imo.

LXRX daily
๐Ÿ‘๏ธ0
BooDog BooDog 1 year ago
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:

โ€œEvaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trialโ€, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.


โ€œEvaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticityโ€, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.


https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html


Looks to be waking up.

LXRX chart
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Bears are on the job. eom


LXRX chart

Message in reply to:
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

I'm looking for around $2. This looks like it's only starting to crack. Of course, news AND SOME VOLUME!!!! would certainly help.

No one answered me about the bear flag. So not sure if anyone did anything.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

LXRX daily


All imo of course.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Nice to see the volume maintaining. Hope some were able to take advantage advantage of the dip.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Nice!! Get'r done LXRX!
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Watching the reset. Told you this a great swing play stock.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $20
6:51 am ET July 1, 2022 (Benzinga) Print
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $18 to $20.

Latest Ratings for LXRX DateFirmActionFromTo

Jan 2021WedbushDowngradesOutperformNeutral Jan 2021JP MorganUpgradesUnderweightNeutral Dec 2020CitigroupUpgradesNeutralBuy

View More Analyst Ratings for LXRX

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BooDog maintains that this is still an excellent swing play bio. At least till their next data set.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
This could push back over $4 before the fun even begins.

LXRX daily

When only a few are even paying attention.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
Awesome. For real.
๐Ÿ‘๏ธ0
BooDog BooDog 2 years ago
โ€œWe expect that the new joint guidelines issued this weekend by the three largest cardiology societies in the United States, along with the new guidelines issued last year by the European Society of Cardiology, will support the emerging adoption of SGLT2 inhibitors as a first line treatment standard across heart failure,โ€ said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer at Lexicon. โ€œWe believe that sotagliflozinโ€™s unique mechanism offers opportunities for differentiation within the class, supported by the results from the SOLOIST-WHF study referenced in the guidelines as well as from the SCORED study, additional analyses from which were presented at the American College of Cardiology 71st Annual Scientific Sessions this weekend.โ€

https://marketwirenews.com/news-releases/lexicon-welcomes-new-guidelines-for-the-management-o-7753296108030739.html


Time to move out of the shadows.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock